The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized.The pipeline prioritization is expected to result in a reduction in workforce of approximately
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 eFFECTOR Therapeutics, Inc. , a leader in the development of selective translation regulator inhibitors for the treatment of cancer,.
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
EFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.